Clemson University has announced its participation in a COVID-19 vaccine trial.
According to the release, multiple higher education institutions are involved in the randomized, controlled study. The release further said the study will "assess infection, viral shedding and subsequent potential transmission in students immunized with the Moderna COVID-19 vaccine."
The clinical trial is co-sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and Department of Health and Human Services (DHHS).
A total of 12,000 students from across the country will be involved in the study.
The release detailed requirements for Clemson's participants.
"Half of Clemson’s enrollees will receive an immediate vaccine and the other half will be randomized for a delayed vaccine four months later. Financial incentives up to $750 will be provided commensurate with a student’s participation. Students must be between 18 and 26 years of age and will be followed for four to five months following enrollment. After receiving the vaccine, students will be required to collect daily nasal swabs and to produce one additional saliva test each week (beyond the current requirement of every seven days)," the release said. "To be eligible for the trial, students must not have tested positive for COVID-19 previously and need to be in the immediate area of Clemson’s main campus for a consecutive five-month period to ensure weekly testing compliance and the delivery of nasal swabs."
Clemson students who want to sign up to take part in the trial can fill out a registration form on PreventCOVIDU.org.
